Skip to content
Exclusive CEO Interviews
Press Releases profile photo

Press Releases

Would you like us to consider a press release for publication? Please email david@onyxnewsroom.com.

Oryon Cell Therapies Reports Phase 1b/2a Data Showing Sustained Motor Improvements in People with Parkinson’s Disease

Oryon Cell Therapies Reports Phase 1b/2a Data Showing Sustained Motor Improvements in People with Parkinson’s Disease

BELMONT, Mass. – March 23, 2026 – Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson’s disease and other neurodegenerative disorders, today announced new clinical and neuroimaging data from an ongoing Phase 1b/2a study evaluating its autologous dopaminergic neuron replacement therapy for

Oryon Cell Therapies Emerges From Stealth Focusing on Autologous Neuron Replacement Therapies for Parkinson’s Disease and Other Neurodegenerative Disorders

Oryon Cell Therapies Emerges From Stealth Focusing on Autologous Neuron Replacement Therapies for Parkinson’s Disease and Other Neurodegenerative Disorders

BELMONT, Mass. – March 23, 2026 – Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, today announced it has emerged from stealth and has closed a new $21 million tranche of its Series A financing, bringing

Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

ZURICH, Switzerland — March 19, 2026 — AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the presentation of new clinical data from the global Phase 2 clinical trial (AP-101-02) evaluating the company’s lead program, AP-101,

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

About Media Contact Legal → Download PDF Corporate Overview Ocugen, Inc. About Ocugen, Inc. ▼ Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike

Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)

Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)

✨ Onyx Summary Affinia Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track designation to AFTX-201, its investigational gene therapy for BAG3-associated dilated cardiomyopathy, which is currently being evaluated in the Phase 1/2 UPBEAT clinical trial. The designation signals regulatory support for accelerating development of

Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM)

Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM)

✨ Onyx Summary Affinia Therapeutics said the European Medicines Agency has granted Orphan Drug designation to AFTX-201, its investigational AAV gene therapy for BAG3-associated dilated cardiomyopathy, following the FDA’s acceptance of its IND. The designation adds regulatory incentives and market-exclusivity potential in the EU as Affinia advances a one-time intravenous

Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors

Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors

✨ Onyx Summary Cellares and the University of Wisconsin School of Medicine and Public Health expanded their partnership to move UW’s CRISPR-edited GD2 CAR-T program for solid tumors into clinical manufacturing and support an FDA IND submission, with Cellares providing automated manufacturing (Cell Shuttle) and automated QC (Cell Q) plus

Verily Pre is Now “Awardable” in DoW’s Tradewinds Solutions Marketplace

Verily Pre is Now “Awardable” in DoW’s Tradewinds Solutions Marketplace

✨ Onyx Summary Verily says its Verily Pre precision health AI platform has achieved “Awardable” status on the Department of War CDAO’s Tradewinds Solutions Marketplace, positioning it as a readily awardable option for DoW agencies. The designation is intended to streamline federal procurement and expands Verily’s path from existing

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

✨ Onyx Summary Recursion’s board compensation committee approved inducement RSU awards covering 820,431 shares to 17 new employees under its 2024 Inducement Equity Incentive Plan, with quarterly vesting beginning after a one-year anniversary milestone and continuing until fully vested, contingent on continued employment. The grants, issued under Nasdaq Rule

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

✨ Onyx Summary Ocugen appointed Rita Johnson-Greene as chief financial officer, citing her leadership experience across regenerative medicine and gene therapy organizations including ARM, bluebird bio (Genetix Biotherapeutics), Spark Therapeutics, and AstraZeneca. The hire comes as Ocugen prepares to submit the first of three planned biologics license applications this year, aligning